| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5843954 | Pharmacology & Therapeutics | 2014 | 11 Pages |
Abstract
Given that diabetes and cancer each account for 8% and 13% of global deaths and there is a substantial financial burden incurred by both disorders, developing diabetes therapies that are safe, efficacious and cost-effective has never been more desirable. This timely review examines recent progress in delineating the molecular mechanisms responsible for the anti-diabetic actions of insulin, metformin and TZDs and considers evidence implicating these therapies in cell transformation and tumourigenesis. In addition, since the endocannabinoid signalling system (ECS) is now considered a therapeutic target and biomarker candidate for hyperglycaemia, obesity and cell growth, a brief section covering recent scientific advances regarding the ECS, particularly its functions in regulating glucose metabolism and cell survival, is also included in this review.
Keywords
IGFBPPPREsIP3CB1RCB2RT2DPIP2mGlPGC-1αIP3R2-arachidonoyl glycerolMCDPEPCKGLUT4Retinoid X receptorGPR55FFAsRXRCPT-12-AGACCIGFAMPKPPAR response elementsFASmTORPPARPPARγ coactivator-1αIRSECsInositol 1,4,5-triphosphatemalonyl-CoA decarboxylaseMAPKTZDsacetyl-CoA carboxylasefatty acid synthaseFree fatty acidsinsulininsulin receptor substrateDiabetesthiazolidinedionesglucose transporter 4Type 2 diabetesCancerendocannabinoid systemAnti-diabeticsInsulin growth factorphosphoenolpyruvate carboxykinasemonoacylglycerol lipaseObesitymitogen-activated protein kinaseadenosine monophosphate-activated protein kinasecarnitine palmitoyltransferase-1Cannabinoidglucose-6-phosphataseInositol 1,4,5-triphosphate receptorinsulin receptorperoxisome proliferator-activated receptorCannabinoid 1 receptorCannabinoid 2 receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Chen Li, Deling Kong,